SG11202003700TA - Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) - Google Patents
Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)Info
- Publication number
- SG11202003700TA SG11202003700TA SG11202003700TA SG11202003700TA SG11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- hepatitis
- virus
- novel
- carboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17199687 | 2017-11-02 | ||
PCT/EP2018/000502 WO2019086141A1 (en) | 2017-11-02 | 2018-11-02 | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003700TA true SG11202003700TA (en) | 2020-05-28 |
Family
ID=60201941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003700TA SG11202003700TA (en) | 2017-11-02 | 2018-11-02 | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
Country Status (23)
Country | Link |
---|---|
US (1) | US11267825B2 (en) |
EP (1) | EP3704127A1 (en) |
JP (1) | JP2021501764A (en) |
KR (1) | KR20200083551A (en) |
CN (1) | CN111448199A (en) |
AR (1) | AR113826A1 (en) |
AU (1) | AU2018361364B2 (en) |
BR (1) | BR112020008762A2 (en) |
CA (1) | CA3081386A1 (en) |
CL (1) | CL2020001145A1 (en) |
CU (1) | CU20200037A7 (en) |
EA (1) | EA202091113A1 (en) |
EC (1) | ECSP20029558A (en) |
GE (1) | GEP20227373B (en) |
IL (1) | IL274298A (en) |
MA (1) | MA50524A (en) |
MX (1) | MX2020004839A (en) |
PH (1) | PH12020550525A1 (en) |
SG (1) | SG11202003700TA (en) |
TW (1) | TW201930315A (en) |
UY (1) | UY37962A (en) |
WO (1) | WO2019086141A1 (en) |
ZA (1) | ZA202002249B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY38434A (en) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) |
UY38436A (en) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) |
SG11202111236UA (en) * | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
KR20230124583A (en) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | Novel spiropyrrolidine-derived antiviral agent |
WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040385A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
DE19817264A1 (en) | 1998-04-18 | 1999-10-21 | Bayer Ag | New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents |
AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
AU3009801A (en) | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
DE10012823A1 (en) | 2000-03-16 | 2001-09-20 | Bayer Ag | New alkyl-6-aminoalkyl-dihydropyrimidine-5-carboxylate derivatives, useful for the treatment of viral, especially hepatitis B, infections |
ES2679744T3 (en) | 2003-11-12 | 2018-08-30 | Daiichi Sankyo Company, Limited | Procedure to produce thiazole derivatives |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
AU2007225273A1 (en) | 2006-03-10 | 2007-09-20 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
UY30867A1 (en) | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | NEW ANALOGS OF PIRIDINA VII 543 |
WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
US8024013B2 (en) | 2008-07-09 | 2011-09-20 | Sony Ericsson Mobile Communications Ab | Regulating power duty cycle of an RF transmitter/receiver responsive to distance moved |
EP2327704A4 (en) | 2008-08-29 | 2012-05-09 | Shionogi & Co | Ring-fused azole derivative having pi3k-inhibiting activity |
WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US9090632B2 (en) | 2010-08-31 | 2015-07-28 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors |
MX354852B (en) | 2010-09-02 | 2018-03-22 | Suven Life Sciences Ltd Star | Heterocyclyl compounds as histamine h3 receptor ligands. |
EP2720695A4 (en) | 2011-06-15 | 2014-11-12 | Nono Inc | Agents and methods for treating ischemic and other diseases |
WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
AP2014007621A0 (en) | 2011-11-11 | 2014-05-31 | Pfizer | 2-Thiopyrimidinones |
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
SG10201605291WA (en) | 2012-08-28 | 2016-08-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
ES2610758T3 (en) | 2012-08-28 | 2017-05-03 | Janssen Sciences Ireland Uc | Condensed bicyclic sulfamoyl derivatives and their use as medicines in the treatment of hepatitis B |
WO2014113191A1 (en) | 2013-01-15 | 2014-07-24 | Xiaohu Zhang | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EA201592126A1 (en) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION |
WO2014184365A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
TR201807090T4 (en) | 2013-07-25 | 2018-06-21 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and its use as medicaments for the treatment of hepatitis. |
ES2739435T3 (en) | 2013-10-18 | 2020-01-31 | Univ Indiana Res & Tech Corp | Hepatitis B viral assembly effectors |
EA201690979A1 (en) | 2013-11-14 | 2016-08-31 | Новира Терапьютикс, Инк. | AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
BR112016020566B1 (en) | 2014-03-07 | 2022-11-29 | F. Hoffmann-La Roche Ag | NOVEL HETEROARYL-DIHYDRO-PYRIMIDINES FUSED IN POSITION 6 FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION |
KR102363174B1 (en) | 2014-03-13 | 2022-02-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | Hepatitis b core protein allosteric modulators |
KR20160133563A (en) | 2014-03-28 | 2016-11-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Dihydropyrimidine compounds and their application in pharmaceuticals |
EP3139954A4 (en) | 2014-05-09 | 2018-02-28 | Indiana University Research and Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
RU2664329C1 (en) | 2014-08-14 | 2018-08-16 | Ф. Хоффманн-Ля Рош Аг | Novel piridazones and triazinones for treatment and preventing of hepatitis b virus infection |
DK3227262T3 (en) | 2014-12-02 | 2020-08-10 | Novira Therapeutics Inc | SULFIDALKYL AND PYRIDYL-REVERSE SULPHONAMIDE COMPOUNDS FOR HBV TREATMENT |
CN107531691A (en) | 2014-12-30 | 2018-01-02 | 诺维拉治疗公司 | Treat the derivative and method of hepatitis B infection |
MA41338B1 (en) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Pyrazine compounds for the treatment of infectious diseases |
CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
MX2017011997A (en) * | 2015-03-18 | 2018-05-28 | Abide Therapeutics Inc | Piperazine carbamates and methods of making and using same. |
US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2016177655A1 (en) | 2015-05-04 | 2016-11-10 | F. Hoffmann-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
CN107849037B (en) | 2015-07-21 | 2020-04-17 | 豪夫迈·罗氏有限公司 | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection |
WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
TWI730985B (en) | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | Hepatitis b core protein modulators |
CA3000197A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CA3004147C (en) | 2015-11-04 | 2019-09-10 | Qilu Pharmaceutical Co., Ltd. | Crystal form, preparation method and intermediate of dihydropyrido ring compound |
WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
CA3017020C (en) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
JP6957518B2 (en) | 2016-05-20 | 2021-11-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | A novel pyrazine compound with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases |
WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
CN109415368B (en) | 2016-07-14 | 2021-04-30 | 豪夫迈·罗氏有限公司 | Carboxy 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine compounds for the treatment of infectious diseases |
EP3484886B1 (en) | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
JOP20190024A1 (en) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
CA3036245C (en) | 2016-09-13 | 2021-07-20 | Arbutus Biopharma Corporation | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
JOP20190105A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
MX2019010404A (en) | 2017-03-02 | 2019-11-21 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same. |
MA49014A (en) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | DIHYDROINDENE-4-CARBOXAMIDES SUBSTITUTED, THEIR ANALOGUES AND PROCESSES FOR THEIR CORRESPONDING USE |
CA3081399A1 (en) * | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2018
- 2018-11-02 AR ARP180103202A patent/AR113826A1/en unknown
- 2018-11-02 KR KR1020207015662A patent/KR20200083551A/en not_active Application Discontinuation
- 2018-11-02 JP JP2020524457A patent/JP2021501764A/en active Pending
- 2018-11-02 MA MA050524A patent/MA50524A/en unknown
- 2018-11-02 BR BR112020008762-9A patent/BR112020008762A2/en not_active IP Right Cessation
- 2018-11-02 EP EP18811439.1A patent/EP3704127A1/en not_active Withdrawn
- 2018-11-02 AU AU2018361364A patent/AU2018361364B2/en not_active Ceased
- 2018-11-02 CA CA3081386A patent/CA3081386A1/en not_active Abandoned
- 2018-11-02 WO PCT/EP2018/000502 patent/WO2019086141A1/en unknown
- 2018-11-02 CN CN201880079554.1A patent/CN111448199A/en active Pending
- 2018-11-02 SG SG11202003700TA patent/SG11202003700TA/en unknown
- 2018-11-02 GE GEAP201815351A patent/GEP20227373B/en unknown
- 2018-11-02 MX MX2020004839A patent/MX2020004839A/en unknown
- 2018-11-02 TW TW107139067A patent/TW201930315A/en unknown
- 2018-11-02 EA EA202091113A patent/EA202091113A1/en unknown
- 2018-11-02 CU CU2020000037A patent/CU20200037A7/en unknown
- 2018-11-02 US US16/761,189 patent/US11267825B2/en active Active
- 2018-11-05 UY UY0001037962A patent/UY37962A/en not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274298A patent/IL274298A/en unknown
- 2020-04-30 PH PH12020550525A patent/PH12020550525A1/en unknown
- 2020-04-30 CL CL2020001145A patent/CL2020001145A1/en unknown
- 2020-05-04 ZA ZA2020/02249A patent/ZA202002249B/en unknown
- 2020-06-01 EC ECSENADI202029558A patent/ECSP20029558A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111448199A (en) | 2020-07-24 |
ECSP20029558A (en) | 2020-07-31 |
AR113826A1 (en) | 2020-06-17 |
CU20200037A7 (en) | 2021-03-11 |
GEP20227373B (en) | 2022-04-25 |
US11267825B2 (en) | 2022-03-08 |
WO2019086141A1 (en) | 2019-05-09 |
IL274298A (en) | 2020-06-30 |
BR112020008762A2 (en) | 2020-10-20 |
MA50524A (en) | 2020-09-09 |
AU2018361364B2 (en) | 2020-11-26 |
JP2021501764A (en) | 2021-01-21 |
PH12020550525A1 (en) | 2021-04-26 |
MX2020004839A (en) | 2020-10-16 |
US20200354379A1 (en) | 2020-11-12 |
EP3704127A1 (en) | 2020-09-09 |
WO2019086141A8 (en) | 2019-08-29 |
AU2018361364A1 (en) | 2020-05-21 |
CL2020001145A1 (en) | 2020-10-09 |
EA202091113A1 (en) | 2020-08-28 |
KR20200083551A (en) | 2020-07-08 |
UY37962A (en) | 2019-05-31 |
ZA202002249B (en) | 2022-01-26 |
TW201930315A (en) | 2019-08-01 |
CA3081386A1 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202003746UA (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
ZA202002249B (en) | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
HK1255847A1 (en) | Vaccines against hepatitis b virus | |
HK1251219A1 (en) | Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection | |
IL267949A (en) | Altered virus | |
EP3360554A4 (en) | Anti-hepatitis b virus agent | |
EP3325097A4 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
EP3283472A4 (en) | Hepatitis b viral assembly effectors | |
ZA201900156B (en) | Phosphoramidates for the treatment of hepatitis b virus | |
EP3675637A4 (en) | Hepatitis b antiviral agents | |
IL275427A (en) | Hepatitis b virus (hbv) vaccines and uses thereof | |
IL265921A (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
IL267785A (en) | Virus | |
IL290924A (en) | Hepatitis b virus vaccines | |
IL266526A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
IL287278A (en) | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) | |
EP3775292A4 (en) | Virus bioresistors | |
IL287227A (en) | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) | |
EP3615054A4 (en) | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS | |
EP3862004A4 (en) | Anti-hepatitis b virus agent | |
IL287269A (en) | Novel oxalyl piperazines active against the hepatitis b virus (hbv) | |
GB201813175D0 (en) | Virus use | |
EP3621645A4 (en) | Bivalent dengue/hepatitis b vaccines | |
GB201702193D0 (en) | Hepatitis E virus vaccine | |
GB201716047D0 (en) | Virus |